Previous Article | Next Article 
Journal of Virology, October 1998, p. 8371-8373, Vol. 72, No. 10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
An Adenovirus Type 5 Mutant with the Preterminal Protein Gene
Deleted Efficiently Provides Helper Functions for the Production of
Recombinant Adeno-Associated Virus
Ian H.
Maxwell,1,2
Francoise
Maxwell,1 and
Jerome
Schaack2,3,4,5,*
Department of
Dermatology,1
University of Colorado
Cancer Center,2
Molecular Biology
Program,3
Biomedical Sciences
Program,4 and
Department of
Microbiology,5 University of Colorado Health
Sciences Center, Denver, Colorado 80262
Received 10 April 1998/Accepted 10 June 1998
 |
ABSTRACT |
Production of recombinant adeno-associated virus (rAAV) requires
helper functions that have routinely been provided by infection of the
producer cells with adenovirus. Complete removal and/or inactivation of
progeny adenovirus, present in such rAAV preparations, presents
significant difficulty. Here, we report that an adenovirus type 5 (Ad5) mutant with the preterminal protein (pTP) gene deleted can
provide helper function for the growth of rAAV. At high multiplicity, Ad5dl308
pTP was as efficient as the
phenotypically wild-type Ad5dl309 in permitting growth of
rAAV. Use of Ad5dl308
pTP, which is incapable
of replication in the absence of complementation for pTP, as a
helper avoids the need to remove contaminating adenovirus infectious
activity by heat inactivation or by purification. Comparison of
the transducing ability of rAAV generated with either
Ad5dl308
pTP or Ad5dl309 as
a helper demonstrated that the heat inactivation protocol generally
used does not remove all of the helper Ad5dl309 function.
 |
TEXT |
The development of
adeno-associated virus (AAV) as a gene transfer vector has been
hindered by a lack of convenient and efficient methods for generating
pure stocks of recombinant AAV (rAAV) (9, 12). A significant
difficulty in this regard is the need to supply helper functions
(1, 2, 5, 6, 18, 19). Although this is
efficiently achieved by adenovirus coinfection of the producer cells,
this results in the concomitant production of adenovirus progeny, which
are difficult to remove or inactivate completely. Contamination with
replication-competent adenovirus is not only unacceptable for
gene therapy applications but also significantly influences the
transduction efficiency achieved with rAAV vectors, thus
complicating assessment of their utility (3, 4). Since
adenovirus early functions are sufficient to support AAV replication
(19), we investigated the use of a mutant blocked in the
late functions as a helper for rAAV production. A deletion mutant
in the preterminal protein (pTP) gene of adenovirus type 5 (Ad5),
termed Ad5dl308
pTP, was previously
described (16), together with complementing,
pTP-expressing cell lines that support productive infection by
this mutant (10, 15). In noncomplementing cells,
Ad5dl308
pTP was shown to be completely defective for DNA synthesis and expression of late functions
(16). In contrast, other adenovirus mutants used to provide
helper function for rAAV show significant leakiness for replication
(18). Here, we report that
Ad5dl308
pTP can function as an efficient
helper for generating rAAV stocks, free from replication-competent
adenovirus.
Stocks of adenovirus helpers, Ad5dl309 and
Ad5dl308
pTP, were produced in 293 cells
and 293-pTP cells (10, 15), respectively. Ad5dl309 has a deletion and insertion in the E3 region
but shows replication equivalent to wild-type Ad5 in cell culture
(8). In contrast, Ad5dl308
pTP
is incapable of either replicating or directing synthesis of late
region products in the absence of complementation. Even with a
sensitive RNase protection assay, late transcripts were undetectable in
293 cells infected with this virus (16). Both helpers were
purified by isopycnic centrifugation in CsCl. The infectious titers
of Ad5dl309 and
Ad5dl308
pTP were determined by plaque
assay in 293 cells and 293-pTP cells, respectively. Since the plaque
assay is technically more difficult in 293-pTP cells, the titer of
Ad5dl308
pTP was verified with absorbance
measurement to determine the particle concentration. We have
consistently observed similar PFU-to-particle ratios (
1:100) for
both Ad5dl309 and
Ad5dl308
pTP.
rAAV was produced by transient cotransfection of
pAAV.CMV.LUC (11) and pAAV/Ad (13, 14)
into the human simian virus 40-transformed cell line 324K by
electroporation; we previously reported advantages of these
modifications of standard transfection methods (11).
pAAV.CMV.LUC contains an rAAV genome with the luciferase
reporter driven by the cytomegalovirus immediate-early promoter
(11). Immediately after electroporation, the cells were
infected either with the phenotypically wild-type
Ad5dl309 or with
Ad5dl308
pTP. Medium was replaced after 2 to 6 h, and culture media and cell extracts containing
AAV.CMV.LUC were harvested at the times indicated
(11). Transducing activities of the resulting rAAV
preparations were determined by infection of fresh, recipient 324K
cells (at 30 to 40% confluence in 12-well plates) and an assay for
luciferase activity in cell extracts prepared 2 days after
infection by using the Promega luciferase assay kit with a Turner
Instruments luminometer.
As shown in Fig. 1,
Ad5dl308
pTP was effective as a helper for
rAAV production, although a higher multiplicity of infection (MOI)
of this virus than of Ad5dl309 was required. Thus,
similar yields of transducing AAV.CMV.LUC were obtained by
using Ad5dl308
pTP at 100 PFU per cell or
Ad5dl309 at 10 PFU/cell. In several experiments performed under these conditions, the apparent yield of
AAV.CMV.LUC obtained with
Ad5dl308
pTP ranged from 64 to 104% of
that with Ad5dl309. Since these measurements were
made with heat-treated virus preparations (see below), these figures
reflect a slight underestimate of the relative yield of
rAAV obtained by using Ad5dl308
pTP as a helper. Yields were
decreased 10- to 100-fold if the MOI of
Ad5dl308
pTP was lowered to 10 PFU/cell
(Fig. 1). The higher MOI required for
Ad5dl308
pTP probably reflects the need to
express helper functions at levels comparable to those provided by
Ad5dl309 after replication. These data demonstrate that Ad5dl308
pTP efficiently provides
helper function for rAAV and, further, that pTP
expression is not required when helper function is provided by
adenovirus infection.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 1.
Efficient production of luciferase-transducing
rAAV with Ad5dl308 pTP as a
helper. 324K cells were suspended and electroporated with
pAAV.CMV.LUC plus pAAV/Ad, as previously described
(11), and were infected by dilution into medium containing
either Ad5dl309 or
Ad5dl308 pTP at the estimated MOI
indicated, expressed as PFU per surviving cell (cell survival from
electroporation was 50%). After 3.5 h, the inoculum was
aspirated and the attached cells were rinsed gently and given fresh
medium. After 4 days, culture supernatants and frozen-thawed cell
extracts were collected (11). Samples were incubated at
56°C for 30 min before being assayed for transducing activity in
fresh recipient 324K cells (11). Values on the ordinate are
luciferase transducing activity (total light units [LU]) calculated
for supernatant plus cell extract; measurements ranged from 3 to 500 LU
above the luminometer background of 0.01 LU. The data shown are from a
representative experiment. In repeated experiments with some variations
in time of exposure to the adenovirus inoculum and time of harvest, the
transducing activities generated (total LU) were (1.15 ± 0.92) × 104 and (2.17 ± 0.26) × 105 with
Ad5dl308 pTP at 10 and 100 PFU/cell,
respectively, and (2.77 ± 0.51) × 105 with
Ad5dl309 (mean ± standard deviation for three
experiments in each case).
|
|
In the experiment represented in Fig. 1, rAAV was harvested at
4 days after transfection/infection of the producer cells. In
further experiments, similar yields of AAV.CMV.LUC
transducing activity were obtained whether harvesting was
performed after 4 or 5 days, although the yield was substantially
lower after only 3 days. Infection with
Ad5dl308
pTP at high MOI (100 PFU/cell)
resulted in considerable cell detachment at later times. However, the
proportion of transducing activity found in cell extract versus
supernatant medium was similar to that reported previously for rAAV
production from 324K cells with Ad5dl309 as a helper
(11). (Approximately 60% of the total activity was recovered in the extract from combined attached plus detached cells
[data not shown].)
The results presented in Fig. 1 were obtained by using samples of
rAAV preparations that had been heated for 30 min at 56°C, prior
to transduction of the recipient cells. A similar heat treatment is
used routinely in many laboratories to inactivate the adenovirus present in rAAV preparations. Figure
2A shows the effects of omission of
this heating step on the transducing activity of AAV.CMV.LUC generated with either helper. This omission increased the
apparent transducing activity of the
Ad5dl309-helped rAAV markedly (50- to 100-fold),
presumably due to the well-established stimulatory effect of adenovirus
coinfection on rAAV transduction, probably mediated via enhancement
of second-strand synthesis (3, 4). In contrast, omission of
heating had little effect (approximately twofold) on transduction by
Ad5dl308
pTP-helped AAV.CMV.LUC (Fig. 2A), consistent with the expected lack of replication of the Ad5dl308
pTP virus in the producer
cells. The minor effect seen was most probably due to thermal
inactivation of a proportion of the rAAV itself.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Absence of contaminating adenovirus helper activity in
AAV.CMV.LUC stock, generated with
Ad5dl308 pTP as a helper, as indicated by
the lack of effect of incubation at 56°C (A) and strong stimulation
of transduction by added adenovirus Ad5dl309 (B). (A)
Samples of the same rAAV preparations as in Fig. 1 were assayed for
transducing activity with (+56°) or without prior incubation at
56°C. Note that this treatment had little effect on the
Ad5dl308 pTP-helped AAV.CMV.LUC,
whereas the apparent transducing activity of the
Ad5dl309-helped rAAV was 100-fold higher when
heat treatment was omitted. (B) Recipient 324K cells were
coinfected with heated cell extracts (56°C, 30 min)
containing AAV.CMV.LUC, generated with either
Ad5dl308 pTP or
Ad5dl309 helper virus, together with
Ad5dl309 added at the MOI indicated. Luciferase
activity, assayed after 2 days, is expressed as percentage of the
activity observed with the maximum amount of added
Ad5dl309 (MOI, 3 PFU per cell). Note the differential
enhancement of transducing activity of the
Ad5dl308 pTP-helped rAAV at low MOI of
added Ad5dl309.
|
|
To examine further the stimulatory effect of coinfecting
adenovirus on transduction, 324K cells were transduced
with AAV.CMV.LUC generated with either helper adenovirus,
together with increasing MOI of added Ad5dl309, and
transduced luciferase activity was assayed after 2 days. As shown in
Fig. 2B, although Ad5dl309 stimulated transduction by
both virus preparations, this effect was considerably stronger
for the Ad5dl308
pTP-helped rAAV
than for the Ad5dl309-helped rAAV, particularly at
lower MOI of added Ad5dl309. We interpret this
result to indicate that the Ad5dl309-helped rAAV
preparation retained a low but significant level of adenovirus that
survived the 56°C treatment and stimulated transduction, so that low
levels of added Ad5dl309 showed little additional
stimulatory effect. These results provide further support for the
absence of contaminating adenovirus from rAAV generated with
Ad5dl308
pTP as helper.
As a further comparison of the yield of rAAV obtained with
Ad5dl308
pTP and Ad5dl309
helpers, we performed semiquantitative PCR on viral DNA with luciferase
primers. Virus samples were first treated extensively with DNase I to
degrade any contaminating plasmid or other DNA not protected by
packaging in virions. As shown in Fig. 3,
similar signal intensities were observed regardless of which adenovirus
helper had been used to generate the AAV.CMV.LUC. These results
further substantiate the conclusion, from relative transducing activity
(Fig. 1), that the Ad5dl308
pTP helper, used at high MOI, gives yields of rAAV comparable to those obtained with a conventional, replication-competent adenovirus helper.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of rAAV yield obtained with
Ad5dl308 pTP (versus
Ad5dl309) helper virus by PCR analysis of packaged
AAV.CMV.LUC DNA. Viral supernatants containing rAAV,
generated with either helper, were incubated with DNase I (200 µg/ml,
37°C, 4 h; control experiments showed complete digestion of
plasmid DNA under these conditions), and the enzyme was inactivated at
64°C for 15 min. PCR was performed with luciferase primers for 30 cycles, as described previously (17), on diluted samples of
the DNase-treated supernatants. Under these conditions, packaged DNA is
rendered available as a template for PCR by disruption of the virions
in the initial incubation at 94°C. The products were analyzed by
electrophoresis in a 1.5% agarose gel and staining with ethidium
bromide. As standards, samples containing the indicated amounts of a
linearized luciferase plasmid were amplified in parallel. Lanes 1 to 4, plasmid standards (0, 3, 30, and 300 fg, respectively); lane 5, marker
DNA (123-bp ladder [GIBCO BRL]); lanes 6 to 8, rAAV generated
with Ad5dl308 pTP helper (samples
equivalent to 1, 10, and 100 nl of supernatant, respectively); lanes 9 to 11, rAAV generated with Ad5dl309 helper (samples
equivalent to 1, 10, and 100 nl of supernatant, respectively).
|
|
In most laboratories, rAAV is routinely produced by transient
cotransfection of a plasmid containing the recombinant genome, together
with a second plasmid expressing AAV Rep and Cap, with concomitant
adenovirus infection of the producer cells to supply the
necessary helper functions (E1A, E1B, E2A, E4 and VA RNA) (9, 12, 19). Efficient introduction of these functions by
virus infection has heretofore been at the cost of contamination of
rAAV by progeny adenovirus. Use of
Ad5dl308
pTP as a helper, as
described here, removes this limitation. An alternative means of
supplying relevant adenovirus functions from a cotransfected expression
plasmid has recently also been shown to give efficient production of
rAAV, free from adenovirus (19). Direct comparison of
the yield of rAAV from this system with those we have
obtained using Ad5dl308
pTP is
difficult for several reasons, relating to the use of different assays
and to the fact that the transfection system also used a novel,
replication-deficient AAV helper plasmid (19). The latter
system requires the use of the 293 cell line to provide E1A and E1B
functions which are not encoded by the Ad5-derived plasmid. In
contrast, Ad5dl308
pTP can be used as
helper for rAAV production in other cells, such as the 324K line,
which offers certain practical advantages as described previously (11). Other systems under development for achieving higher
production of rAAV seek to avoid transfection procedures by
incorporating conditionally expressed AAV helper sequences
(rep and cap) into an adenovirus helper or
into herpes simplex virus-based helpers (2, 7). Such an
approach based on pTP-deleted adenovirus might enable high
efficiency of rAAV production without generating adenovirus
progeny.
 |
ACKNOWLEDGMENTS |
This work was supported by a grant from the Monfort Foundation to
I.H.M. and by NIH grant RO1 HL58344 to J.S.
We thank Lih-Jen Su for production and titration of
Ad5dl309.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, University of Colorado Health Sciences Center, 4200 E. Ninth Ave., Denver, CO 80262. Phone: (303) 315-6883. Fax: (303) 315-6785. E-mail: jerry.schaack{at}uchsc.edu.
 |
REFERENCES |
| 1.
|
Clark, K. R.,
F. Voulgaropoulou,
D. M. Fraley, and P. R. Johnson.
1995.
Cell lines for the production of recombinant adeno-associated virus.
Hum. Gene Ther.
6:1329-1341[Medline].
|
| 2.
|
Conway, J. E.,
S. Zolotukhin,
N. Muzyczka,
G. S. Hayward, and B. J. Byrne.
1997.
Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.
J. Virol.
71:8780-8789[Abstract].
|
| 3.
|
Ferrari, F. K.,
T. Samulski,
T. Shenk, and R. J. Samulski.
1996.
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.
J. Virol.
70:3227-3234[Abstract].
|
| 4.
|
Fisher, K. J.,
G. P. Gao,
W. D. Weitzman,
R. DeMatteo,
J. F. Burda, and J. M. Wilson.
1996.
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.
J. Virol.
70:520-532[Abstract].
|
| 5.
|
Fisher, K. J.,
W. M. Kelley,
J. F. Burda, and J. M. Wilson.
1996.
A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome.
Hum. Gene Ther.
7:2079-2087[Medline].
|
| 6.
|
Flotte, T. R.,
X. Barraza-Ortiz,
R. Solow,
S. A. Afione,
B. J. Carter, and W. B. Guggino.
1995.
An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction.
Gene Ther.
2:29-37[Medline].
|
| 7.
|
Johnston, K. M.,
D. Jacoby,
P. A. Pechan,
C. Fraefel,
P. Borghesani,
D. Schuback,
R. J. Dunn,
F. I. Smith, and X. O. Breakefield.
1997.
HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.
Hum. Gene Ther.
8:359-370[Medline].
|
| 8.
|
Jones, N., and T. Shenk.
1978.
Isolation of deletion and substitution mutants of adenovirus type 5.
Cell
13:181-188[Medline].
|
| 9.
|
Kotin, R. M.
1994.
Prospects for the use of adeno-associated virus as a vector for human gene therapy.
Hum. Gene Ther.
5:793-801[Medline].
|
| 10.
|
Langer, S. J., and J. Schaack.
1996.
293 cell lines that inducibly express high levels of adenovirus type 5 precursor terminal protein.
Virology
221:172-179[Medline].
|
| 11.
|
Maxwell, F.,
G. S. Harrison, and I. H. Maxwell.
1997.
Improved production of recombinant AAV by transient transfection of NB324K cells using electroporation.
J. Virol. Methods
63:129-136[Medline].
|
| 12.
|
Muzyczka, N.
1992.
Use of adeno-associated virus as a general transduction vector for mammalian cells.
Curr. Top. Microbiol. Immunol.
158:97-129[Medline].
|
| 13.
|
Samulski, R. J.,
L. S. Chang, and T. Shenk.
1987.
A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication.
J. Virol.
61:3096-3101[Abstract/Free Full Text].
|
| 14.
|
Samulski, R. J.,
L. S. Chang, and T. Shenk.
1989.
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.
J. Virol.
63:3822-3828[Abstract/Free Full Text].
|
| 15.
|
Schaack, J.,
X. Guo,
W. Y. Ho,
M. Karlok,
C. Chen, and D. Ornelles.
1995.
Adenovirus type 5 precursor terminal protein-expressing 293 and HeLa cell lines.
J. Virol.
69:4079-4085[Abstract].
|
| 16.
|
Schaack, J.,
X. Guo, and S. J. Langer.
1996.
Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene.
Proc. Natl. Acad. Sci. USA
93:14686-14691[Abstract/Free Full Text].
|
| 17.
|
Spitzer, A. L.,
F. Maxwell,
J. Corsini, and I. H. Maxwell.
1996.
Species specificity for transduction of cultured cells by a recombinant LuIII rodent parvovirus genome encapsidated by canine parvovirus or feline panleukopenia virus.
J. Gen. Virol.
77:1787-1792[Abstract/Free Full Text].
|
| 18.
|
Vincent, K. A.,
S. T. Piraino, and S. C. Wadsworth.
1997.
Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products.
J. Virol.
71:1897-1905[Abstract].
|
| 19.
|
Xiao, X.,
L. Li, and R. J. Samulski.
1998.
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.
J. Virol.
72:2224-2232[Abstract/Free Full Text].
|
Journal of Virology, October 1998, p. 8371-8373, Vol. 72, No. 10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.